Platinum Investment Management Ltd. acquired a new position in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 20,800 shares of the biotechnology company’s stock, valued at approximately $850,000. Platinum Investment Management Ltd. owned 0.07% of Five Prime Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in FPRX. Creative Planning grew its stake in Five Prime Therapeutics by 0.8% during the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after buying an additional 54 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in Five Prime Therapeutics during the third quarter worth approximately $223,000. Legal & General Group Plc grew its stake in Five Prime Therapeutics by 3.1% during the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock worth $288,000 after buying an additional 287 shares during the period. Virtu KCG Holdings LLC purchased a new stake in Five Prime Therapeutics during the second quarter worth approximately $331,000. Finally, Dupont Capital Management Corp purchased a new stake in Five Prime Therapeutics during the third quarter worth approximately $341,000. Institutional investors own 83.80% of the company’s stock.

In other news, Director William R. Ringo sold 2,000 shares of the company’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $38.00, for a total value of $76,000.00. Following the completion of the transaction, the director now directly owns 2,000 shares in the company, valued at $76,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William R. Ringo sold 600 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $45.33, for a total transaction of $27,198.00. Following the completion of the transaction, the director now owns 600 shares of the company’s stock, valued at $27,198. The disclosure for this sale can be found here. Insiders sold 4,400 shares of company stock valued at $175,666 over the last 90 days. Insiders own 6.50% of the company’s stock.

Five Prime Therapeutics Inc (NASDAQ:FPRX) opened at $24.57 on Wednesday. Five Prime Therapeutics Inc has a 52 week low of $21.41 and a 52 week high of $59.62.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.19). The firm had revenue of $8.33 million during the quarter, compared to analysts’ expectations of $16.16 million. Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. Five Prime Therapeutics’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.72) earnings per share. equities research analysts expect that Five Prime Therapeutics Inc will post -5.56 earnings per share for the current fiscal year.

Several research firms have issued reports on FPRX. ValuEngine downgraded shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. BMO Capital Markets boosted their price objective on shares of Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 7th. Jefferies Group restated a “buy” rating and issued a $52.00 target price on shares of Five Prime Therapeutics in a research note on Tuesday, September 12th. Finally, Royal Bank Of Canada restated a “buy” rating and issued a $41.00 target price on shares of Five Prime Therapeutics in a research note on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Five Prime Therapeutics currently has an average rating of “Hold” and an average target price of $64.00.

TRADEMARK VIOLATION WARNING: This piece was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://theolympiareport.com/2017/12/06/platinum-investment-management-ltd-takes-position-in-five-prime-therapeutics-inc-fprx.html.

Five Prime Therapeutics Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.